Abnormal Porphyrin Metabolism in Autism Spectrum Disorder and Therapeutic Implications.
Neluwa-Liyanage Ruwan IndikaUdara Dilrukshi SenarathneAntonio MalvasoDhanushka DarshanaSusan C OwensBorhan MansouriYuliya SemenovaGeir BjørklundPublished in: Molecular neurobiology (2023)
Autism spectrum disorder (ASD) is a mosaic of neurodevelopmental conditions composed of early-onset social interaction and communication deficits, along with repetitive and/or restricted patterns of activities, behavior, and interests. ASD affects around 1% of children worldwide, with a male predominance. Energy, porphyrin, and neurotransmitter homeostasis are the key metabolic pathways affected by heavy metal exposure, potentially implicated in the pathogenesis of ASD. Exposure to heavy metals can lead to an altered porphyrin metabolism due to enzyme inhibition by heavy metals. Heavy metal exposure, inborn genetic susceptibility, and abnormal thiol and selenol metabolism may play a significant role in the urinary porphyrin profile anomalies observed in ASD. Altered porphyrin metabolism in ASD may also be associated with, vitamin B6 deficiency, hyperoxalemia, hyperhomocysteinemia, and hypomagnesemia. The present review considers the abnormal porphyrin metabolism in ASD in relation to the potential pathogenic mechanism and discusses the possible metabolic therapies such as vitamins, minerals, cofactors, and antioxidants that need to be explored in future research. Such targeted therapeutic therapies would bring about favorable outcomes such as improvements in core and co-occurring symptoms.
Keyphrases
- autism spectrum disorder
- heavy metals
- photodynamic therapy
- attention deficit hyperactivity disorder
- intellectual disability
- early onset
- risk assessment
- metal organic framework
- health risk assessment
- health risk
- energy transfer
- electron transfer
- sewage sludge
- late onset
- healthcare
- traumatic brain injury
- young adults
- high frequency
- type diabetes
- dna methylation
- depressive symptoms
- cancer therapy
- current status
- drug delivery
- insulin resistance